More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning. Raising its price target on the shares to $21, ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...
The 36-year-old rapper-singer-flautist successfully lowered her body mass index (BMI) by 10.5 and lost 16% of her body fat on ...
Stocktwits on MSN21h
Hims & Hers Hits New Highs On At-Home Lab Testing Plans: Retail Sees More Room To Run, Analysts DividedHims & Hers Health, Inc. shares surged 17.5% on Wednesday, marking their best performance in a week and hitting fresh highs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback